5′-UMP inhibited muscle atrophy due to detraining: a randomized, double-blinded, placebo-controlled, parallel-group comparative study

被引:0
|
作者
Inoue, Mika [1 ]
Kubota, Atsushi [2 ]
Takazawa, Yuji [2 ,3 ]
Nakagawara, Kosuke [4 ]
Ishige, Kazuya [4 ]
Suzuki, Yoshio [2 ]
机构
[1] Juntendo Univ, Juntendo Adm Sports Hlth & Med Sci, Tokyo, Japan
[2] Juntendo Univ, Grad Sch Hlth & Sports Sci, Chiba, Japan
[3] Juntendo Univ, Grad Sch Med, Tokyo, Japan
[4] YAMASA Corp, Biochem Div, Chiba, Japan
来源
关键词
muscle thickness; resistance training; sarcopenia; UMP; uridine 5 '-monophosphate; HUMAN QUADRICEPS MUSCLE; HUMAN SKELETAL-MUSCLE; PROTEIN-SYNTHESIS; GENE-EXPRESSION; MESSENGER-RNA; IMMOBILIZATION; PGC-1-ALPHA; INTENSITY; RESISTANCE; TURNOVER;
D O I
10.3389/fspor.2024.1403215
中图分类号
G8 [体育];
学科分类号
04 ; 0403 ;
摘要
Purpose A short period of disuse of 1-2 weeks due to factors such as illness or injury can lead to muscle atrophy, affecting both athletic performance and health. Recent research has shown that uridine 5 '-monophosphate (5 '-UMP) can counteract disuse-induced muscle atrophy by increasing PGC-1 alpha expression and inhibiting atrogin-1 expression. However, the effect of 5 '-UMP on disuse muscle atrophy in humans remains unknown. Therefore, the aimed of this study was to explore the effects of 5 '-UMP supplementation during detraining on short-term disuse muscle atrophy in healthy men.Methods Following a 6-week resistance training program on upper arm, healthy men were randomized to either a UMP group (n = 11) or a placebo group (n = 10), taking their respective supplements during the 2-week detraining period. Muscle thickness, an indicator of muscle hypertrophy and atrophy, was measured at 3 positions (MT50, MT60, and MT70) at baseline, 1 week, and 2 weeks after detraining.Results Both groups showed a significant decrease in muscle thickness at MT70. The relative decrease was greater in the placebo group (2.4 +/- 2.8%) than in the UMP group (0.0 +/- 2.0%), significantly (p = 0.034) at 1 week. However, no significant difference was observed at MT50 and MT60.Conclusion After the hypertrophy, 5 '-UMP may prevent muscle atrophy due to the detraining within the first week.
引用
收藏
页数:8
相关论文
共 50 条
  • [21] Heat-Killed Lactococcus lactis subsp. cremoris H61 Altered the Iron Status of Young Women: A Randomized, Double-Blinded, Placebo-Controlled, Parallel-Group Comparative Study
    Takaragawa, Mizuki
    Sakuraba, Keishoku
    Suzuki, Yoshio
    NUTRIENTS, 2022, 14 (15)
  • [22] Protein C zymogen in severe sepsis: a double-blinded, placebo-controlled, randomized study
    Pappalardo, Federico
    Crivellari, Martina
    Di Prima, Ambra L.
    Agracheva, Nataliya
    Celinska-Spodar, Malgorzata
    Lembo, Rosalba
    Taddeo, Daiana
    Landoni, Giovanni
    Zangrillo, Alberto
    INTENSIVE CARE MEDICINE, 2016, 42 (11) : 1706 - 1714
  • [23] Dexamethasone on postoperative gastrointestinal motility: A placebo-controlled, double-blinded, randomized controlled trial
    Chen, Yuezhi
    Dong, Chenyang
    Lian, Guodong
    Li, Dongsheng
    Yin, Yuehan
    Yu, Wenhai
    Du, Changkun
    Liu, Chen
    Li, Leping
    Tian, Feng
    Jing, Changqing
    JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 2020, 35 (09) : 1549 - 1554
  • [24] Double-blinded, randomized, placebo-controlled study to evaluate the effectiveness of sulphasalazine in preventing acute gastrointestinal complications due to radiotherapy
    Kiliç, D
    Egehan, I
    Özenirler, S
    Dursun, A
    RADIOTHERAPY AND ONCOLOGY, 2000, 57 (02) : 125 - 129
  • [25] A phase 2b, randomized, double-blinded, parallel-group, placebo-controlled study to evaluate the efficacy and safety of rezpegaldesleukin in adults with severe to very-severe alopecia areata
    Rosmarin, David
    Sadick, Neil
    Rodgers, Timothy G.
    Lain, Edward
    Osman, Lawrence
    Schleicher, Stephen
    Reich, Adam
    Szepietowski, Jacek C.
    Owczarczyk-Saczonek, Agnieszka
    Baran, Wojciech
    Kwiek, Bartlomiej
    Torz, Michal
    Zdybski, Jacek
    Chaudhry, Sohail
    Lee, Zachary
    Xu, Heng
    Liu, Yi
    Lewis, Brian
    Mellskog, Katie
    Elko-Simms, Lucinda M.
    Fanton, Christie
    Tagliaferri, Mary
    Zalevsky, Jonathan
    Lynde, Charles W.
    BRITISH JOURNAL OF DERMATOLOGY, 2024, 191
  • [26] Gaboxadol in angelman syndrome: A double-blind, parallel-group, randomized placebo-controlled phase 3 study
    Keary, Christopher
    Bird, Lynne M.
    de Wit, Marie-Claire
    Hatti, Shivkumar
    Heimer, Gali
    Heussler, Helen
    Kolevzon, Alexander
    Mathews, Adera
    Ochoa-Lubinoff, Cesar
    Tan, Wen-Hann
    Yan, Ying
    Adams, Maxwell
    EUROPEAN JOURNAL OF PAEDIATRIC NEUROLOGY, 2023, 47 : 6 - 12
  • [27] Effects of Fortetropin on the Rate of Muscle Protein Synthesis in Older Men and Women: A Randomized, Double-Blinded, Placebo-Controlled Study
    Evans, William
    Shankaran, Mahalakshmi
    Nyangau, Edna
    Field, Tyler
    Mohammed, Hussein
    Wolfe, Robert
    Schutzler, Scott
    Hellerstein, Marc
    JOURNALS OF GERONTOLOGY SERIES A-BIOLOGICAL SCIENCES AND MEDICAL SCIENCES, 2021, 76 (01): : 108 - 114
  • [28] Pericapsular nerve group (PENG) block for hip arthroscopy: a randomized, double-blinded, placebo-controlled trial
    Amato, Peter E.
    Coleman, John R.
    Dobrzanski, Tomasz P.
    Elmer, Donald A.
    Gwathmey, Frank W., Jr.
    Slee, April E.
    Hanson, Neil A.
    REGIONAL ANESTHESIA AND PAIN MEDICINE, 2022, 47 (12) : 728 - 732
  • [29] Effects of Fortetropin on the Rate of Muscle Protein Synthesis in Older Men and Women: A Randomized, Double-Blinded, Placebo-Controlled Study
    Evans, William
    Shankaran, Mahalakshmi
    Nyangau, Edna
    Field, Tyler
    Mohammed, Hussein
    Wolfe, Robert
    Schutzler, Scott
    Hellerstein, Marc
    JOURNALS OF GERONTOLOGY SERIES A-BIOLOGICAL SCIENCES AND MEDICAL SCIENCES, 2020, 76 (01): : 108 - 114
  • [30] Efficacy of resveratrol in the treatment of unipolar depression: double-blind randomized placebo-controlled parallel-group study
    Aftanas, L. I.
    Markov, A. A.
    Rikita, M. V.
    Danilenko, K. V.
    EUROPEAN NEUROPSYCHOPHARMACOLOGY, 2020, 40 : S189 - S189